Nurix Therapeutics Inc. (NRIX) has reported promising results from its ongoing clinical trial of NX-5948, aimed at treating patients with relapsed refractory chronic lymphocytic leukemia (CLL). The company plans to advance NX-5948 into pivotal trials by 2025.
Pre-market trading on Nasdaq saw Nurix shares surge approximately 14.3%, reaching $17.35 per share.
The latest clinical data concerning NX-5948, an orally bioavailable degrader of Bruton's tyrosine kinase (BTK), was showcased at the European Hematology Association Congress (EHA2024).
NX-5948 is currently being assessed in a Phase 1a/b clinical trial involving adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL).
The data unveiled at EHA include safety findings for all patients in the Phase 1a dose escalation study, irrespective of diagnosis, and efficacy findings for those with relapsed or refractory CLL.
During the trial, participants received daily oral doses of NX-5948, ranging from 50 mg to 600 mg. The drug was well tolerated across all evaluated doses, with common treatment-emergent adverse events being purpura/contusion, thrombocytopenia, and neutropenia.
Kim Linton, a clinical trial investigator, remarked, “The current results from this study of advanced patients are very impressive for this early stage of development. We are optimistic that NX-5948 has the potential to be a significant breakthrough for patients with relapsed CLL, especially given the emerging resistance patterns to currently available targeted therapies. As a clinical investigator, it is highly gratifying to offer patients who are refractory to other treatments a once-daily oral drug that can manage various CLL disease states.”
Linton also presented a detailed case report, highlighting the response of a patient with CLL and CNS involvement, who had previously undergone three therapies, including a BTK inhibitor.
Following daily treatment with 100 mg, and later 300 mg, of NX-5948, the patient showed a significant improvement, approaching complete response criteria by 36 weeks, and the elimination of malignant cells in the cerebrospinal fluid by 24 weeks.
For more health news, visit rttnews.com.
